latest updates
- Latest 21:05: US Equities Close Lower
- 20:25: US Stock Performance
- 17:10: Myovant Sciences Shares Surge
- 16:35: European Equities Close Lower
- 16:04: CURO Group Stock Surges
- 15:02: Mereo BioPharma, Ultragenyx Team-Up
- 14:33: US Equities Positive
- 14:22: Palantir Technologies
- 14:19: Mesoblast Stock Falls
- 10:45: UK Stock Gainers
- 09:31: Synairgen Shares Surge
- 08:05: European Equities
Latest
21:05
US Equities Close Lower
- DOW: -0.38%
- S&P: -0.19%
- NASDAQ: -0.07%
20:25
US Stock Performance
17:10
Myovant Sciences Shares Surge
$MYOV Myovant Sciences shares are rallied over 8% reaching highs of $26.78 after the company got FDA approval of Orgovyx for the treatment of advanced prostate cancer.
16:35
European Equities Close Lower
- FTSE 100: -0.38%
- DAX: -0.21%
- STOXX 50: -0.44%
- IBEX 35: -1.42%
- CAC 40: -0.39%
16:04
CURO Group Stock Surges
Consumer finance firm, CURO Group’s (NYSE: CURO) share price has skyrocketed after it said on Friday that the company is set to benefit from Katapult’s announced merger with SPAC, FinServ Acquisition Corp (NASDAQ: FSRV)
Full Story: CURO GROUP STOCK SURGES ON NEWS IT WILL BENEFIT FROM KATAPULT AND FINSERV MERGER
CURO: +127.93% $20.03
15:02
Mereo BioPharma, Ultragenyx Team-Up
Mereo BioPharma (NASDAQ: MREO, AIM: MPH) shares are rallying premarket on Friday after the company announced a license and collaboration agreement with Ultragenyx Pharmaceutical (NASDAQ: RARE) for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).
Full Story: MEREO BIOPHARMA STOCK SURGES ON NEWS OF ULTRAGENYX COLLABORATION
Mereo BioPharma: +47.06% $3.25
14:33
US Equities Positive
- DOW: +0.05%
- S&P: +0.02%
- NASDAQ: +0.21%
14:22
Palantir Technologies
Palantir Technologies (NYSE: PLTR) shares are trading 3.67% lower at $26.23 after Credit Suisse downgraded the stock from Neutral to Underperform and announced a $17 price target.
14:19
Mesoblast Stock Falls
Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.
Full Story: MESOBLAST STOCK PLUMMETS 31% AFTER TRIAL LOOKS UNLIKELY TO MEET ENDPOINT
10:45
UK Stock Gainers
- Synairgen: +41.65%: SYNAIRGEN SHARES SURGE 25% AFTER SNG001 AWARDED FDA FAST TRACK STATUS
- United Carpets Group: +19.05%: The company is proposing delisting from the AIM as the directors believe that the company is not of a sufficient scale to attract interest from institutional and other investors.
- Mining Minerals & Metals: +15.23%
- AFC Energy: +15.22%: AFC ENERGY SHARES SURGE 18% ON NEWS OF ABB EV CHARGING PARTNERSHIP
09:31
Synairgen Shares Surge
Shares of biotechnology company Synairgen (LON: SNG) are rallying on Friday after the company provided an update on its Phase 3 trial evaluating SNG001 as a treatment for Covid-19.
Full Story: SYNAIRGEN SHARES SURGE 25% AFTER SNG001 AWARDED FDA FAST TRACK STATUS
08:05
European Equities
- FTSE 100: -0.04%
- DAX: -0.13%
- STOXX 50: -0.23%
- IBEX 35: -0.40%
- CAC 40: -0.20%
Overnight News:
- Coinbase files confidentially for an IPO
- Coca-Cola will cut about 2,200 jobs globally
- The FDA votes to endorse Moderna’s coronavirus vaccine
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .